


<div style="text-align: center;">  <p> INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use several sheets if necessary)</small> </p> </div>				Complete if Known			
Sheet 1 of 3				Application Number	10/634,477		
				Filing Date	August 4, 2003		
				First Name Inventor	Lehmann, et al.		
				Attorney Docket Number	21368 US		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
✓	A1	5,733,761		Treco et al.	03/31/1998		
	A2	5,641,670		Treco et al.	06/24/1997		
	A3	5,733,746		Treco et al.	03/31/1998		
	A4	5,994,127		Selden et al.	11/30/1999		
	A5	6,528,313		Le Mouellie et al.	03/04/2003		
	A6	5,981,214		Skoultschi	11/09/1999		
	A7	5,272,071		Chappel	12/21/1993		
	A8	5,359,030		Ekuribe	10/25/1994		
	A9	5,681,811		Ekuribe	10/28/1997		
	A10	4,179,337		Davis et al.	12/18/1979		
	A11	5,324,650		Obzansky et al.	06/28/1994		
	A12	6,583,272		Bailon	06/24/2003		
	A13	5,672,662		Harris et al.	09/30/1997		
	A14	5,541,158		Vance et al.	07/30/1996		
	A15	4,745,099		Akamatsu et al.	05/17/1988		
	A16	6,333,306		Lehmann et al.	12/25/2001		
	A17	US 2002/0160956 A1		Lehmann et al.	10/2002		
	A18	5,376,632		Konings et al.	12/27/1994		
	✓	A19	6,372,715		Kaltwasser et al.	04/16/2002	
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁴	
		Office ³	Number ³				Kind Code ² (if known)
✓	B1	EP	640619		Amgen Inc.	03/01/1995	
	B2	WO	01/02017		F. Hoffmann-La Roche AG	01/11/2001	
	B3	EP	1064951		F. Hoffmann-La Roche AG	01/03/2001	
	B4	EP	539167		Ortho Pharmaceutical Corp.	04/28/1993	
	B5	EP	605963		Ortho Pharmaceutical Corp.	07/13/1994	
	B6	WO	93/25212		Amgen Inc.	12/23/1993	
	B7	WO	94/20069		Amgen Inc.	09/15/1994	
	B8	WO	95/11924		Enzon, Inc.	05/04/1995	
	B9	EP	584876		Sterling Winthrop Inc.	03/02/1994	
	B10	WO	92/16555		Enzon, Inc.	10/01/1992	
	B11	WO	94/28024		Enzon, Inc.	12/08/1994	
	✓	B12	WO	97/04796		Protein Delivery Inc.	02/13/1997
	B13	WO	98/32466		Polymase Pharmaceutical PLC	07/30/1998	

¹ EXAMINER, Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique design designation number. ³ See attached Kind of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.1). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 14 if possible. ⁷ Applicant to place a check mark here if English language Translation or abstract is attached.



Submission Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Complete if Known Application Number 10/634,477 Filing Date August 4, 2003 First Name Inventor Lehmann, et al.	
Sheet	2	of	3
		Attorney Docket Number	21368 US

FOREIGN PATENT DOCUMENTS

B14	DE 3924705	Boehringer Mannheim GmbH	01/31/1991
B15	WO 01/87329	F. Hoffmann-La Roche AG	11/22/2001
B16	EP 0411678	Genetics Institute Inc.	02/06/1991
B17	EP 0205564	Genetics Institute Inc.	12/30/1986
B18	EP 0286439	Ortho Pharmaceutical Corp.	10/12/1988
B19	WO 97/09996	Boehringer Mannheim GmbH	03/20/1997
B20	WO 98/41226	Boehringer Mannheim GmbH	09/24/1998

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
[Handwritten marks]	C1	P. Lehmann, M. Volkman, J. Lotz, A. Baldauf, R. Roediger, poster presented at the AACC/SCCC, Annual Meeting, July 29 - August 2, 2001, Chicago Illinois	
	C2	Abstract corresponding to DE 3924705, 1991	
	C3	Grützner P., et al., <i>Clinical Nephrology</i> , vol. 38, pp 92-97, 1992	
	C4	Wick, M.; Pinggera, W.; Lehmann, P., <i>Eisenstoffwechsel Diagnostik und Therapie der Anämien</i> , 3 rd edition, Springer, Wien, NY, pp 5-14, 38-55, 65-80, 94-98, Sept. 1996	
	C5	Sunder-Plassmann G., et al., <i>Journal of the American Society of Nephrology</i> , 5, (3), pp 478 (1994).	
	C6	Gasche C., et al., <i>Dig. Dis. Sci.</i> , 39, (9) pp 1930-4 (1994).	
	C7	Sunder-Plassmann G., et al., <i>Nephrology Dialysis Transplantation</i> , 10, (11), pp 2070-2076 (1995).	
	C8	Mercuriali F. et al., <i>Erythropoiesis: New Dimensions in the Treatment of Anaemia</i> , 6/3, pp 67-76, (1995).	
	C9	Sunder-Plassmann G., et al., <i>Nephrology Dialysis Transplantation</i> , 11, (9), pp 1797-1802, (1996).	
	C10	Taylor J. E., et al., <i>Nephrology Dialysis Transplantation</i> , 11, (6), pp 1079-1083, (1996).	
[Handwritten marks]	C11	Braymann, et al., <i>Eur. J. Clin. Invest.</i> , pp 123-30.	
	C12	Goodnough, et al., <i>Haematology</i> , 1(2), pp 163-166.	
	C13	MacDougall (1994) Monitoring of Iron Status & Iron Supplementation in Patients Treated with Erythropoietin. <i>Current Opinion in Nephrology & Hypertension</i> 3(6) pgs. 620-625	
[Handwritten marks]	C14	Taylor et al. (1996) Regular low-dose Intravenous Iron Therapy Improves Response to Erythropoietin in Haemodialysis Patients. <i>Nephrology, Dialysis, & Transplantation</i> 11(6) pgs. 1079-1083	
	C15	Means, Jr. (1995) Erythropoietin in the Treatment of Anemia in Chronic Infectious, Inflammatory, & Malignant Diseases. <i>Current Opinion in Hematology</i> 2(3) pgs. 210-213	

Improper citation

Improper



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Complete if Known			
		Application Number	10/634,477		
		Filing Date	August 4, 2003		
		First Name Inventor	Lehmann, et al.		
Sheet	3	of	3	Attorney Docket Number	21368 US

NON PATENT LITERATURE DOCUMENTS

	C16	Adamson (1996) Erythropoietin, Iron Metabolism, & Red Blood Cell Production. <i>Seminars In Hematology</i> 33(2) pgs. 5-9	
	C17	Mercuriali & Inghilleri (1995) Iron Administration to Optimize the Effect of r-HuEPO in the Surgical Setting. Erythropoiesis: <i>New Dimensions in the Treatment of Anemia</i> 6(3) pgs. 67-76	
	C18	Pincus et al. (August, 1990) Multicultural Study of Recombinant Human Erythropoietin in Correction of Anemia in Rheumatoid Arthritis. <i>The American Journal of Medicine</i> 89(2) pgs. 161-168.	
Examiner Signature			DATE CONSIDERED 8/30/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 *Unique citation designation number. *Applicant is to place a check mark here if English language Translation or abstract is attached.